Cancer Immunology, Immunotherapy

, Volume 56, Issue 9, pp 1323–1334

Role of IL-21 in immune-regulation and tumor immunotherapy

  • Emma di Carlo
  • Daniela de Totero
  • Tiziana Piazza
  • Marina Fabbi
  • Silvano Ferrini
Review

DOI: 10.1007/s00262-007-0326-z

Cite this article as:
di Carlo, E., de Totero, D., Piazza, T. et al. Cancer Immunol Immunother (2007) 56: 1323. doi:10.1007/s00262-007-0326-z

Abstract

IL-21, the most recently discovered member of the IL-2 cytokine family, is an attractive subject for research due to its involvement in experimental models of autoimmunity, its ability to down-regulate IgE production, and its anti-tumor properties. Its interest for cancer immunotherapy stems from its physiological immune-enhancing functions. These include regulation of T, B and NK cell proliferation, survival, differentiation, and effector functions. IL-21’s functional activities partially overlap those of IL-2. Both cytokines display similar structural features and use the common γ-chain receptor and its downstream signaling pathways. Besides its activities on normal lymphoid cells, IL-21 is an in vitro growth factor for myeloma and acute-T cell leukemia cells, whereas it induces the apoptosis of B-CLL (chronic lymphocytic leukemia) cells. These findings indicate that the IL-21/IL-21R system exerts opposite functions in different lymphoid neoplasias, and suggest its employment in B-CLL therapy. Since IL-2, but not IL-21, is specifically required for the development of regulatory T (Treg) cell immune-suppressive functions, IL-21 may be a new tool for cancer immunotherapy. It is, in fact, a powerful anti-tumor agent in a variety of murine experimental tumor models through its activation of specific or innate immune responses against neoplastic cells. The preliminary data from phase-I clinical studies suggest that the use of IL-21 is feasible and may result in immune-enhancing effects.

Keywords

Interleukin-21Immune-regulationLymphoid neoplasiaTumor immunotherapy

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • Emma di Carlo
    • 1
  • Daniela de Totero
    • 2
  • Tiziana Piazza
    • 2
  • Marina Fabbi
    • 2
  • Silvano Ferrini
    • 2
  1. 1.Dipartimento di Oncologia e Neuroscienze, Sezione di Patologia Chirurgica, and Ce.S.I. Aging Research CenterFondazione Universitaria “G. d’Annunzio”ChietiItaly
  2. 2.Immunotherapy UnitIstituto Nazionale per la Ricerca sul CancroGenoaItaly